2F-Ketamine (2-FDCK)

2F-Ketamine (2-FDCK): Research Chemical Profile, Structure, and Legal Status

2F-Ketamine, also known as 2-FDCK (2-Fluorodeschloroketamine), is a dissociative anesthetic research chemical structurally related to ketamine and deschloroketamine (DCK). It belongs to the arylcyclohexylamine class and is studied primarily for its NMDA receptor antagonism, which contributes to its dissociative effects.

Although 2F-Ketamine shares similarities with its better-known analogs, it is not approved for medical or veterinary use and is supplied strictly for laboratory research purposes.

What is 2F-Ketamine (2-FDCK)?

2F-Ketamine is a fluorinated analog of ketamine, with a fluorine atom replacing a chlorine atom on the phenyl ring. This modification alters the molecule’s binding profile, metabolic rate, and possibly its potency — though conclusive scientific data remains limited.

  • IUPAC Name: 2-(2-Fluorophenyl)-2-methylamino-cyclohexanone

  • Molecular Formula: C13H16FNO

  • Chemical Class: Arylcyclohexylamine, dissociative anesthetic

  • Common Form: White crystalline powder

Its chemical behavior is believed to involve antagonism of NMDA receptors, which can induce dissociative and anesthetic-like effects in laboratory models.

Reported Effects (Anecdotal)

There is no clinical or medical research confirming 2F-Ketamine’s pharmacological effects in humans. However, anecdotal reports from independent researchers and chemical analysis forums suggest it may produce effects similar to ketamine, such as:

  • Dissociation or detachment from surroundings

  • Altered perception of time and body

  • Reduced physical sensitivity

  • Cognitive suppression

  • Tranquilizing or anesthetic-like response

These effects are speculative and must not be interpreted as safe or therapeutic. All research must occur in professionally controlled environments.

Safety and Handling Considerations

As with all arylcyclohexylamine-based compounds, 2F-Ketamine poses potential risks if mishandled. Limited toxicological data means all laboratory procedures must prioritize safety and minimize exposure.

Potential safety concerns include:

  • Neurotoxicity (unknown but suspected)

  • Disorientation and cognitive impairment

  • Elevated heart rate or blood pressure

  • Respiratory suppression in high concentrations

  • Risk of improper metabolism and accumulation

Only trained laboratory personnel should handle 2F-Ketamine. It must be stored in secure, temperature-stable conditions away from unauthorized access.

Legal Status of 2F-Ketamine (2-FDCK)

The legal status of 2F-Ketamine varies by region, often depending on its structural similarity to ketamine and other dissociatives.

  • United States: Not explicitly scheduled, but may be regulated under the Federal Analog Act

  • United Kingdom: Considered a controlled substance under the Misuse of Drugs Act (Class B)

  • Germany: Covered under the NpSG (New Psychoactive Substances Act)

  • Canada & Australia: Often regulated under analog laws related to arylcyclohexylamines

  • EU: Legal status varies by member state; commonly restricted under NPS monitoring systems

Researchers must verify current legal classification before importing, handling, or studying 2F-Ketamine.

For Research Use Only

2F-Ketamine (2-FDCK) is offered solely for scientific, analytical, and forensic research. It is not approved for human or animal consumption and should never be used outside of a qualified laboratory setting.

Researchers are responsible for adhering to all local and international regulations when handling this compound.

Would you like to develop additional resources like:

  • A comparison article (e.g., “2F-Ketamine vs Ketamine: Chemical Differences”)

  • Internal links to related arylcyclohexylamines (e.g., MXE, DCK)

  • A legal summary page or downloadable SDS?

Shopping Cart